Drug Development Pipeline
ABBV-2222 (formerly GLPG2222)
Restore CFTR Function
ABBV-2222 (formerly GLPG2222) is a type of CFTR modulator called a corrector. Correctors are drugs designed to fix and restore the function of the defective CFTR protein. The corrected CFTR then moves to the cell surface, where it functions as a chloride channel and helps maintain the right balance of fluid in the airways.
A phase 2a study to test the safety and tolerability of ABBV-2222 in people with CF who have two copies of the F508del CFTR mutation has been completed.
A phase 2 study to test ABBV-2222 in combination with ABBV-3067, a CFTR potentiator, is underway.
This program is sponsored by Abbvie and is being conducted within the Therapeutics Development Network.
Recent ABBV-2222 (formerly GLPG2222) Studies
Completed with Results
Phase 2a study of Galapagos GLPG2222 in adults with CF (GLPG2222-CL-202)
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More